See the DrugPatentWatch profile for Esperoct
Esperoct is a medication used for the treatment of hemophilia A [1].
What is Esperoct approved for?
Esperoct, also known by its nonproprietary name turoctocog alfa, is approved for routine prophylaxis and treatment of bleeding episodes in individuals with hemophilia A [1][2]. It is a recombinant coagulation factor VIII (rFVIII) concentrate [1].
How does Esperoct work?
Esperoct is a long-acting form of recombinant factor VIII. It has a modified half-life, meaning it remains in the body for a longer duration compared to conventional factor VIII products, allowing for less frequent dosing [1][2]. This is achieved through fusion of the factor VIII molecule with an Fc fragment of human immunoglobulin G1 [1].
When does Esperoct's patent expire?
Information regarding the specific patent expiry dates for Esperoct is not publicly available through the provided text. DrugPatentWatch.com is a resource that tracks pharmaceutical patents, which may offer further details [3].
Who manufactures Esperoct?
Esperoct is manufactured by Novo Nordisk [1].
How does Esperoct compare to other hemophilia A treatments?
Esperoct is designed for routine prophylaxis, aiming to prevent bleeding events. Compared to on-demand treatment, which addresses bleeding after it occurs, prophylaxis with Esperoct can reduce the frequency of bleeds. Its extended half-life distinguishes it from earlier rFVIII products that required more frequent administration [1][2].
What clinical trials have been conducted for Esperoct?
Clinical trials have demonstrated Esperoct's efficacy in reducing annualized bleeding rates in patients with hemophilia A. The trials involved both children and adults, comparing different dosing regimens to assess its safety and effectiveness for routine prophylaxis and on-demand treatment [1][2].
Are there any alternatives to Esperoct for hemophilia A?
Beyond Esperoct, other treatment options for hemophilia A include conventional rFVIII concentrates, plasma-derived factor VIII, and bypassing agents for patients who develop inhibitors to factor VIII. Newer therapies like gene therapy are also emerging as potential alternatives [4].